United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - everolimus - dispersible tablet - 5mg

Israel - English - Ministry of Health

novartis israel ltd - everolimus - tablets dispersible - everolimus 2 mg - everolimus - votubia is indicated as adjunctive treatment of patients aged 2 years and older whose refractory epileptic seizures are associated with tuberous sclerosis complex (tsc).

Israel - English - Ministry of Health

novartis israel ltd - everolimus - tablets dispersible - everolimus 3 mg - everolimus - votubia is indicated as adjunctive treatment of patients aged 2 years and older whose refractory epileptic seizures are associated with tuberous sclerosis complex (tsc).

United States - English - NLM (National Library of Medicine)

humphreys pharmacal, incorporated - menthol, unspecified form (unii: l7t10eip3a) (menthol, unspecified form - unii:l7t10eip3a) - menthol 12.5 mg in 1 ml - analgesia tópica / topical anaglesic para un alivio temporal de dolores musculares y dolores en las articulaciones asociados con: - artritis - moretones - esguinces - tensión - achaques de espalda for the temporary relief of minor aches and pains of muscles and joints associated with: - arthritis - bruises - sprains - strains - simple backache no use este producto si su piel es sensible al aceite de menta-verde (salicilato de metilo). no aplique a heridas ni a la piel maltratada. no ponga un vendaje muy apretado. do not use if skin is sensitive to oil of wintergreen (methylsalicylate). do not apply to wounds or damaged skin. do not bandage tightly. inflamable. mantenga alejado del fuego, chispas y superficies calientes. flammable keep away from fire, sparks and heated surfaces.

Singapore - English - HSA (Health Sciences Authority)

ge healthcare pte. ltd. - sodium iodide [i-131] - injection - 74 mbq/ml - sodium iodide [i-131] 74 mbq/ml

Singapore - English - HSA (Health Sciences Authority)

ge healthcare pte. ltd. - sodium iodide [i-131] - injection - 925 mbq/ml - sodium iodide [i-131] 925 mbq/ml

Israel - English - Ministry of Health

j-c health care ltd - infliximab - powder for concentrate for infusion - infliximab 100.0 mg/vial - infliximab - infliximab - - adult :- crohn's disease: treatment of moderate to severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. - paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy - ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. - psoriatic arthritis : remicade is indicated for : treatment of active and progressive psoriatic arthritis in adults when the response to previous dmard therapy has been inadequate. remicade should be administered : either in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. - remicade has been shown to improve physical function in patients with psoriatic arthritis and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease. - rheumatoid arthritis: remicade in combination with methotrexate is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: patients with active disease when the response to disease-modifying drugs including methotrexate has been inadequate. patients with severe active and progressive disease not previously treated with methotrexate or other dmards. in this these patient populations a reduction in the rate of the progression of joint damage as measured by x-ray has been demonstrated - psoriasis: remicade is indicated for: treatment of moderate to severe plaque psoriasis in adults who failed to respond to or who have a contraindication to or are intolerant to other systemic therapy including cyclosporine methotrexate or puva. - ulcerative colitis: remicade is indicated for: treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to convential therapy including corticosteroids and 6-mp or aza or who are intolerant to or have medical contraindications for such therapies.- paediatric ulcerative colitis: remicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 mp or aza, or who are intolerant to or have medical contraindications for such therapies

Ireland - English - HPRA (Health Products Regulatory Authority)

statens serum institute - mycobacterium bovis (bcg) stam 1331 - pdr+solv for susp for inj - %v/v - tuberculosis vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

aj vaccines a/s - mycobacterium bovis (bcg) stam 1331 - powder and solvent for suspension for injection - 0 colony forming unit(s)/millilitre - tuberculosis vaccines; tuberculosis, live attenuated

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - 44670 - bladder instillation, barrier - procedure pack consisting of a clear plastic pre-filled syringe containing a sterile aqueous solution of hyaluronic acid sodium salt (1.6%), sodium chondroitin sulphate (2%) and calcium chloride administered as a bladder instillation via connection to a catheter using the leur lock adaptor and the ialuadapter included in the pack. the ialuadapter allows for administration by either the patient or healthcare professional. ialuril is indicated to re-establish the glycosaminoglycan layers (gags) of the urothelial vesical tissue in cases in which their loss can cause frequent and recurring problems such as painful bladder syndrome (pbs), interstitial cystitis, treatment and prevention of recurrent urinary tract infection, cystitis as a result of bacillus calmette ? guerin therapy, or chemical and radiation therapy. ialuril is also indicated in the cases where the loss of the glycosaminoglycan layers (gags) is associated with forms of chronic inflammation, in which their composition and integrity appears compromised in different ways.